How would you approach the management of a patient with Stage IV NSCLC harboring both a classical and non-classical compound EGFR mutations?  

For instance, how would you manage a patient with both EGFR L858R and EGFR A647T mutations? Additionally, does the presence of brain metastasis influence your treatment strategy?